Austar LifesciencesAULSF 48 EBIT per Share is $0.02 as of Dec. 2025. GuruFocus rates AULSF with a GF Score™ of 48/100 and a GF Value™ of $0.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Austar Lifesciences ranks worse than 92.15% on this metric.
Austar Lifesciences's EBIT per Share for the
six
months ended in Dec. 2025 was $0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.
During the past 12 months, the average EBIT per Share Growth Rate of Austar Lifesciences was -2.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -35.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Austar Lifesciences's EBIT per Share or its related term are showing as below:
AULSF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -36.2 Med: -35.3 Max: 199.6
Current: -35.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Austar Lifesciences was 199.60% per year. The lowest was -36.20% per year. And the median was -35.30% per year.
AULSF's 3-Year EBIT Growth Rate is ranked worse than 92.15% of 688
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs AULSF: -35.30
Austar Lifesciences (OTCPK:AULSF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Austar Lifesciences EBIT per Share Related Terms
Austar Lifesciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a EBIT per Share of $0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Austar Lifesciences and its competitors. According to the industry distribution chart, Austar Lifesciences ranks #634 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 92.2%.
Is Austar Lifesciences' EBIT per Share too high?
Austar Lifesciences' current EBIT per Share is $0.02. The Medical Devices & Instruments industry median EBIT per Share is 9.50. Austar Lifesciences' value of $0.02 is 99.8% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #634 out of 688 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Austar Lifesciences has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #634 out of 688 companies for EBIT per Share. This places Austar Lifesciences in the lower half of its industry. The industry median EBIT per Share is 9.50. Austar Lifesciences' value of $0.02 is 99.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current EBIT per Share of $0.02 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current EBIT per Share is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Austar Lifesciences (AULSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.02 — trading 75% below its estimated fair value. The current EBIT per Share is $0.02 and 99.8% below the Medical Devices & Instruments industry median of 9.50. Austar Lifesciences' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current EBIT per Share is $0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 75% below its estimated GF Value™ of $0.08.
GuruFocus considers Austar Lifesciences to be Possible Value Trap.
Key valuation signals for AULSF:
EBIT per Share: $0.02
GF Value™: $0.08 vs. price of $0.02 (75% below fair value)
Industry Position: 99.8% below the Medical Devices & Instruments median (#634 of 688)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
48GF Score
Get the complete analysis for AULSF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
